US Federal Trade Commissioner Christine Wilson’s plan to resign, which she announced in a 14 February Wall Street Journal commentary, will leave the agency with three Democratic commissioners and no voice to oppose their enforcement actions. The situation may make the pharmaceutical industry more vulnerable to FTC challenges of proposed mergers, but will likely not change outcomes.
Wilson harshly criticized FTC Chair Lina Khan, saying she was making a “noisy exit” in the face of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?